Biotech Delivers 'Great' Phase 2 Data in NASH

Contributed Opinion
  ()
John McCamant of the Medical Technology Stock Letter raised his target price on this company given the earning potential of a once-a-day oral treatment for liver disease in what could be a $35 billion market. read more >

Coverage Initiated on 'One of the Most Undervalued Biotech Companies in Canada'

Research Report
  ()
David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm. read more >

Immuno-Oncology Candidate Yields 'Impressive' Early Clinical Results

  ()
This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts. read more >

Biotech Advances Potential 'Billion-Dollar Drug' with New Trial Launch in China

Research Report
  ()
Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies. read more >

Drug in Combination with Merck's Blockbuster Keytruda Nearly Doubles Response Rate

Contributed Opinion
  ()
Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation. read more >

Potential Alzheimer's Therapies Focus on Early Intervention

Research Report
  ()
After attending a conference on the latest in development of Alzheimer's disease treatments, Andrew Fein, an analyst with H.C. Wainwright & Co., provided an industry update. read more >

Analysts Say Medical Device Firm Sees Record Quarterly Revenue Growth, 120% YOY

  ()
Following the company's release of its latest financial report, three analysts weighed in on the results. read more >
Expert Investing Ideas

"We are initiating coverage on RVX with a Buy rating."

–David Kideckel, Beacon Securities Ltd.


"We believe 2018 could prove to be a pivotal year for DRRX."

–Francois Brisebois, Laidlaw & Company


"We continue to be positive about DRRX's story."

–Grant Zeng, Zacks Small-Cap Research


"DRRX is now highly attractive as a potential speculative play."

–Terry Chrisomalis, Biotech Analysis Central


"VIVE's Q3/17 revenue of ~$4.1M compares to our $3.7M estimate."

–Brian Marckx, Zacks Small-Cap Research


"DRRX will initiate three Phase 2 trials in the near term."

–Francois Brisebois, Laidlaw & Company


INNOVATION MEETS MONEY AT BIOTECH SHOWCASE EXCLUSIVE INVESTOR EVENT

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

Analyst's 'Top Pick' Advances Vaccine Candidates

Research Report
  ()
Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus. read more >

'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate

Research Report
  ()
André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer. read more >

Maxim's Target Price on Biotech Makes It More Than a Tenbagger

Research Report
  ()
Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets. read more >

Stock Price Jump Reflects Biotech's Active October

Research Report
  ()
This immunotherapy firm's stock recently doubled its Nov. 7 price following lots of news, including a clinical data release, a trial launch and an executive appointment. read more >